Aurinia Pharmaceuticals Inc.
AUPHHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. With a market capitalization of $2.05B, it sits in mid-cap territory. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Market Cap
$2.05B
Beta
1.42
P/E (TTM)
7.39
P/E (Fwd)
14.28
EPS (TTM)
$2.16
EPS (Fwd)
$1.12
ROE
65.0%
ROA
13.7%
Cash
$378.5M
Total Debt
$68.6M
Free CF
$124.6M
52W Change
85.2%
Annual Financials
Cash vs Debt
With $378.5M in cash and $68.6M in debt, AUPH maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $124.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 65.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 13.7% further supports the picture of efficient asset utilization. Revenue has grown from $134.0M (2022) to $283.1M (2025), reflecting a 111% increase over the period.
With cash comfortably exceeding debt, AUPH has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aurinia Pharmaceuticals Inc.'s trajectory.